Clinical trial NCT00623623: STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
Official title: STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within 6-24 Hours or Rescue Coronary Intervention Versus a Strategy of Standard Primary PCI in Patients With Acute Myocardial Infarction Within 3 Hours of Onset of Symptoms
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Myocardial Infarction
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2008-02-26
Enrollment: 1899
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims at evaluating, in a proof of concept approach, the outcome of patients presenting with acute ST-elevation myocardial infarction within 3 hours of symptom onset in either a pre-hospital setting or community hospital emergency room without a PCI facility. Following randomisation a strategy of early tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation within 6-24 hours with timely coronary intervention as appropriate (or by rescue coronary intervention if required) in Group A will be compared to primary PCI performed according to local standards in Group B.

The study is exploratory in nature and will examine this medical question. The efficacy and safety endpoints as well as mixed (efficacy and safety) composite endpoints up to or before 30 days following randomisation will be evaluated.

All clinical endpoints of main interest will be assessed as single or composite endpoints for evaluation of the trial objective. All statistical tests are of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.


Eligibility criteria: Inclusion criteria:

1. Age equal or greater than 18 years
2. Onset of symptoms \< 3 hours prior to randomisation 3.12-lead ECG indicative of an acute STEMI

4.Informed consent received

Exclusion criteria:

Medical history, procedures, medication administration or the presence of factors that would in general predispose to bleeding events and/or the inability to evaluate the study primary endpoint

Primary outcomes:
measure: Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.
timeFrame: 30 days
Secondary outcomes:
measure: Number of Patients With All Cause Mortality
timeFrame: 30 days
measure: Number of Patients With Cardiac Mortality
timeFrame: 30 days
measure: Number of Patients With Cardiogenic Shock
timeFrame: 30 days
measure: Number of Patients With Congestive Heart Failure (CHF)
timeFrame: 30 days
measure: Number of Patients With Recurrent Myocardial Infarction (Reinfarction)
timeFrame: 30 days
measure: Number of Patients With Rehospitalisation for Cardiac Reasons
timeFrame: 30 days
measure: Number of Patients With Rehospitalisation for Non-cardiac Reasons
timeFrame: 30 days
measure: Number of Patients With Serious Repeat Target Vessel Revascularization
timeFrame: 30 days
measure: Number of Patients With All Cause Death and Shock
timeFrame: 30 days
measure: Number of Patients With All Cause Death and Shock and CHF
timeFrame: 30 days
measure: Number of Patients With All Cause Death and Shock and Reinfarction
timeFrame: 30 days
measure: Number of Patients With Total Fatal Stroke
timeFrame: 30 days
measure: Number of Patients With Total Disabling Stroke
timeFrame: 30 days
measure: Number of Patients With Total Non-disabling Stroke
timeFrame: 30 days
measure: Number of Patients With Intracranial Haemorrhage
timeFrame: 30 days
measure: Number of Patients With Ischaemic Stroke
timeFrame: 30 days
measure: Number of Patients With Total Stroke (All Types)
timeFrame: 30 days
measure: Number of Patients With Major Non-intracranial Bleeds Including Blood Transfusions
timeFrame: 30 days
measure: Number of Patients With Minor Non-intracranial Bleeds
timeFrame: 30 days
measure: Number of Patients With Total Non-intracranial Bleeds
timeFrame: 30 days
measure: Number of Patients With Serious Resuscitated Ventricular Fibrillation
timeFrame: 30 days
measure: Number of Patients With Serious Resuscitated Ventricular Fibrillation in Association With Invasive Procedures
timeFrame: 30 days
measure: Number of Patients With All Cause Death and Non-fatal Stroke
timeFrame: 30 days
measure: Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke
timeFrame: 30 days
Other outcomes:
Locations:
city: Salzburg
country: Austria
facility: 1123.28.43009 Boehringer Ingelheim Investigational Site
city: Salzburg
country: Austria
facility: 1123.28.43010 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 1123.28.43001 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 1123.28.43002 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 1123.28.43003 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 1123.28.43004 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 1123.28.43005 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 1123.28.43007 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 1123.28.43008 Boehringer Ingelheim Investigational Site
city: Bornem
country: Belgium
facility: 1123.28.32060 Boehringer Ingelheim Investigational Site
city: Bruxelles
country: Belgium
facility: 1123.28.32010 Boehringer Ingelheim Investigational Site
city: Herentals
country: Belgium
facility: 1123.28.32070 Boehringer Ingelheim Investigational Site
city: Liège
country: Belgium
facility: 1123.28.32040 Boehringer Ingelheim Investigational Site
city: Brasilia
country: Brazil
facility: 1123.28.55010 Boehringer Ingelheim Investigational Site
city: Brasilia
country: Brazil
facility: 1123.28.55020 Boehringer Ingelheim Investigational Site
city: Cabo Frio
country: Brazil
facility: 1123.28.55008 Boehringer Ingelheim Investigational Site
city: Campinas
country: Brazil
facility: 1123.28.55017 Boehringer Ingelheim Investigational Site
city: Porto Alegre
country: Brazil
facility: 1123.28.55007 Boehringer Ingelheim Investigational Site
city: Recife
country: Brazil
facility: 1123.28.55001 Boehringer Ingelheim Investigational Site
city: Rio de Janeiro
country: Brazil
facility: 1123.28.55018 Boehringer Ingelheim Investigational Site
city: Rio de Janeiro
country: Brazil
facility: 1123.28.55028 Boehringer Ingelheim Investigational Site
city: Sao Lourenço do Sul
country: Brazil
facility: 1123.28.55016 Boehringer Ingelheim Investigational Site
city: Sao Paulo
country: Brazil
facility: 1123.28.55004 Boehringer Ingelheim Investigational Site
city: Sao Paulo
country: Brazil
facility: 1123.28.55014 Boehringer Ingelheim Investigational Site
city: Edmonton
country: Canada
facility: 1123.28.11006 Boehringer Ingelheim Investigational Site
state: Alberta
city: Edmonton
country: Canada
facility: 1123.28.11505 Boehringer Ingelheim Investigational Site
state: Alberta
city: Newmarket
country: Canada
facility: 1123.28.11002 Boehringer Ingelheim Investigational Site
state: Ontario
city: Santiago
country: Chile
facility: 1123.28.13001 Boehringer Ingelheim Investigational Site
city: Santiago
country: Chile
facility: 1123.28.13002 Boehringer Ingelheim Investigational Site
city: Santiago
country: Chile
facility: 1123.28.13003 Boehringer Ingelheim Investigational Site
city: Santiago
country: Chile
facility: 1123.28.13004 Boehringer Ingelheim Investigational Site
city: Santiago
country: Chile
facility: 1123.28.13005 Boehringer Ingelheim Investigational Site
city: Santiago
country: Chile
facility: 1123.28.13006 Boehringer Ingelheim Investigational Site
city: Ambérieu en Bugey
country: France
facility: 1123.28.3376A Boehringer Ingelheim Investigational Site
city: Aubervilliers Cedex
country: France
facility: 1123.28.3329A Boehringer Ingelheim Investigational Site
city: Aubervilliers Cedex
country: France
facility: 1123.28.3329B Boehringer Ingelheim Investigational Site
city: Aubervilliers Cedex
country: France
facility: 1123.28.3329C Boehringer Ingelheim Investigational Site
city: Besancon
country: France
facility: 1123.28.3351A Boehringer Ingelheim Investigational Site
city: Besancon
country: France
facility: 1123.28.3351B Boehringer Ingelheim Investigational Site
city: Besançon cedex
country: France
facility: 1123.28.3315A Boehringer Ingelheim Investigational Site
city: Besançon cedex
country: France
facility: 1123.28.3315B Boehringer Ingelheim Investigational Site
city: Bobigny
country: France
facility: 1123.28.3302A Boehringer Ingelheim Investigational Site
city: Bobigny
country: France
facility: 1123.28.3302B Boehringer Ingelheim Investigational Site
city: Bordeaux Cedex
country: France
facility: 1123.28.3319A Boehringer Ingelheim Investigational Site
city: Bordeaux Cedex
country: France
facility: 1123.28.3319B Boehringer Ingelheim Investigational Site
city: Bordeaux Cedex
country: France
facility: 1123.28.3319C Boehringer Ingelheim Investigational Site
city: Bourg en Bresse
country: France
facility: 1123.28.3374A Boehringer Ingelheim Investigational Site
city: Bourg en Bresse
country: France
facility: 1123.28.3385A Boehringer Ingelheim Investigational Site
city: Bourg-en-Bresse
country: France
facility: 1123.28.3383A Boehringer Ingelheim Investigational Site
city: Bourges
country: France
facility: 1123.28.3347A Boehringer Ingelheim Investigational Site
city: Bourges
country: France
facility: 1123.28.3347B Boehringer Ingelheim Investigational Site
city: Bourges
country: France
facility: 1123.28.3347C Boehringer Ingelheim Investigational Site
city: Bron
country: France
facility: 1123.28.3355A Boehringer Ingelheim Investigational Site
city: Bron
country: France
facility: 1123.28.3355B Boehringer Ingelheim Investigational Site
city: Caluire et Cuire
country: France
facility: 1123.28.3382A Boehringer Ingelheim Investigational Site
city: Châteauroux cedex
country: France
facility: 1123.28.3311A Boehringer Ingelheim Investigational Site
city: Châteauroux cedex
country: France
facility: 1123.28.3311B Boehringer Ingelheim Investigational Site
city: Châteauroux cedex
country: France
facility: 1123.28.3346A Boehringer Ingelheim Investigational Site
city: Châteauroux cedex
country: France
facility: 1123.28.3346B Boehringer Ingelheim Investigational Site
city: Clichy Cedex
country: France
facility: 1123.28.3303A Boehringer Ingelheim Investigational Site
city: Dreux
country: France
facility: 1123.28.3309A Boehringer Ingelheim Investigational Site
city: Dreux
country: France
facility: 1123.28.3342A Boehringer Ingelheim Investigational Site
city: Evecquemont
country: France
facility: 1123.28.3337A Boehringer Ingelheim Investigational Site
city: Fort De France Cedex
country: France
facility: 1123.28.3387A Boehringer Ingelheim Investigational Site
city: Fort De France Cedex
country: France
facility: 1123.28.3388A Boehringer Ingelheim Investigational Site
city: Grenoble
country: France
facility: 1123.28.3353A Boehringer Ingelheim Investigational Site
city: Grenoble
country: France
facility: 1123.28.3353B Boehringer Ingelheim Investigational Site
city: La Tronche
country: France
facility: 1123.28.3317A Boehringer Ingelheim Investigational Site
city: La Tronche
country: France
facility: 1123.28.3317B Boehringer Ingelheim Investigational Site
city: Le Chesnay Cedex
country: France
facility: 1123.28.3339A Boehringer Ingelheim Investigational Site
city: Le Chesnay Cedex
country: France
facility: 1123.28.3339B Boehringer Ingelheim Investigational Site
city: Le Chesnay
country: France
facility: 1123.28.3307A Boehringer Ingelheim Investigational Site
city: Le Port-Marly
country: France
facility: 1123.28.3336A Boehringer Ingelheim Investigational Site
city: Lille Cedex
country: France
facility: 1123.28.3301A Boehringer Ingelheim Investigational Site
city: Lille Cedex
country: France
facility: 1123.28.3301B Boehringer Ingelheim Investigational Site
city: Lille cedex
country: France
facility: 1123.28.3325A Boehringer Ingelheim Investigational Site
city: Lille cedex
country: France
facility: 1123.28.3325B Boehringer Ingelheim Investigational Site
city: Lille
country: France
facility: 1123.28.3326A Boehringer Ingelheim Investigational Site
city: Lyon cedex 3
country: France
facility: 1123.28.3318A Boehringer Ingelheim Investigational Site
city: Lyon cedex 3
country: France
facility: 1123.28.3318B Boehringer Ingelheim Investigational Site
city: Lyon cedex 3
country: France
facility: 1123.28.3318C Boehringer Ingelheim Investigational Site
city: Lyon cedex 4
country: France
facility: 1123.28.3369A Boehringer Ingelheim Investigational Site
city: Lyon cedex 4
country: France
facility: 1123.28.3369B Boehringer Ingelheim Investigational Site
city: Lyon cedex 7
country: France
facility: 1123.28.3356A Boehringer Ingelheim Investigational Site
city: Lyon cedex 7
country: France
facility: 1123.28.3356B Boehringer Ingelheim Investigational Site
city: Melun cedex
country: France
facility: 1123.28.3308A Boehringer Ingelheim Investigational Site
city: Melun cedex
country: France
facility: 1123.28.3308B Boehringer Ingelheim Investigational Site
city: Melun
country: France
facility: 1123.28.3340A Boehringer Ingelheim Investigational Site
city: Melun
country: France
facility: 1123.28.3340B Boehringer Ingelheim Investigational Site
city: Montelimar Cedex
country: France
facility: 1123.28.3379A Boehringer Ingelheim Investigational Site
city: Montfermeil
country: France
facility: 1123.28.3328A Boehringer Ingelheim Investigational Site
city: Montfermeil
country: France
facility: 1123.28.3328B Boehringer Ingelheim Investigational Site
city: Montfermeil
country: France
facility: 1123.28.3328C Boehringer Ingelheim Investigational Site
city: Nantes Cedex 1
country: France
facility: 1123.28.3349A Boehringer Ingelheim Investigational Site
city: Nantes Cedex 1
country: France
facility: 1123.28.3349B Boehringer Ingelheim Investigational Site
city: Nantes
country: France
facility: 1123.28.3313A Boehringer Ingelheim Investigational Site
city: Nantes
country: France
facility: 1123.28.3313B Boehringer Ingelheim Investigational Site
city: Nice cedex 1
country: France
facility: 1123.28.3322A Boehringer Ingelheim Investigational Site
city: Nice cedex 1
country: France
facility: 1123.28.3322B Boehringer Ingelheim Investigational Site
city: Nice cedex 1
country: France
facility: 1123.28.3322C Boehringer Ingelheim Investigational Site
city: Nice cedex 1
country: France
facility: 1123.28.3366A Boehringer Ingelheim Investigational Site
city: Oyonnax
country: France
facility: 1123.28.3375A Boehringer Ingelheim Investigational Site
city: Paris cedex 10
country: France
facility: 1123.28.3334A Boehringer Ingelheim Investigational Site
city: Paris
country: France
facility: 1123.28.3331A Boehringer Ingelheim Investigational Site
city: Paris
country: France
facility: 1123.28.3371A Boehringer Ingelheim Investigational Site
city: Pessac
country: France
facility: 1123.28.3357A Boehringer Ingelheim Investigational Site
city: Poissy
country: France
facility: 1123.28.3338A Boehringer Ingelheim Investigational Site
city: Pringy Cedex
country: France
facility: 1123.28.3316A Boehringer Ingelheim Investigational Site
city: Pringy Cedex
country: France
facility: 1123.28.3352A Boehringer Ingelheim Investigational Site
city: Quincy-sous-Senart
country: France
facility: 1123.28.3341A Boehringer Ingelheim Investigational Site
city: Romans sur Isère
country: France
facility: 1123.28.3378A Boehringer Ingelheim Investigational Site
city: Rouen cedex
country: France
facility: 1123.28.3310A Boehringer Ingelheim Investigational Site
city: Rouen cedex
country: France
facility: 1123.28.3310B Boehringer Ingelheim Investigational Site
city: Rouen Cedex
country: France
facility: 1123.28.3344A Boehringer Ingelheim Investigational Site
city: Rouen
country: France
facility: 1123.28.3345A Boehringer Ingelheim Investigational Site
city: Rouen
country: France
facility: 1123.28.3345B Boehringer Ingelheim Investigational Site
city: Rouen
country: France
facility: 1123.28.3345C Boehringer Ingelheim Investigational Site
city: Valence Cedex 9
country: France
facility: 1123.28.3377A Boehringer Ingelheim Investigational Site
city: Valence Cedex 9
country: France
facility: 1123.28.3384A Boehringer Ingelheim Investigational Site
city: Vienne Cedex 9
country: France
facility: 1123.28.3373A Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 1123.28.49002 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 1123.28.49006 Boehringer Ingelheim Investigational Site
city: Dortmund
country: Germany
facility: 1123.28.49008 Boehringer Ingelheim Investigational Site
city: Duisburg
country: Germany
facility: 1123.28.49012 Boehringer Ingelheim Investigational Site
city: Frankenthal
country: Germany
facility: 1123.28.49052 Boehringer Ingelheim Investigational Site
city: Sömmerda
country: Germany
facility: 1123.28.49026 Boehringer Ingelheim Investigational Site
city: Alexandroupolis
country: Greece
facility: 1123.28.30012 Boehringer Ingelheim Investigational Site
city: Athens
country: Greece
facility: 1123.28.30001 Boehringer Ingelheim Investigational Site
city: Chalikida
country: Greece
facility: 1123.28.30003 Boehringer Ingelheim Investigational Site
city: Katerini
country: Greece
facility: 1123.28.30011 Boehringer Ingelheim Investigational Site
city: Kavala
country: Greece
facility: 1123.28.30014 Boehringer Ingelheim Investigational Site
city: Korinthos
country: Greece
facility: 1123.28.30006 Boehringer Ingelheim Investigational Site
city: Leivadia
country: Greece
facility: 1123.28.30002 Boehringer Ingelheim Investigational Site
city: Thessaloniki
country: Greece
facility: 1123.28.30007 Boehringer Ingelheim Investigational Site
city: Thessaloniki
country: Greece
facility: 1123.28.30010 Boehringer Ingelheim Investigational Site
city: Thiva
country: Greece
facility: 1123.28.30005 Boehringer Ingelheim Investigational Site
city: Veroia
country: Greece
facility: 1123.28.30009 Boehringer Ingelheim Investigational Site
city: Ferrara
country: Italy
facility: 1123.28.39201 Boehringer Ingelheim Investigational Site
city: Genova
country: Italy
facility: 1123.28.39002A Boehringer Ingelheim Investigational Site
city: Genova
country: Italy
facility: 1123.28.39022 Boehringer Ingelheim Investigational Site
city: Imperia
country: Italy
facility: 1123.28.39004A Boehringer Ingelheim Investigational Site
city: Lagosanto (FE)
country: Italy
facility: 1123.28.39200A Boehringer Ingelheim Investigational Site
city: Monza
country: Italy
facility: 1123.28.39001A Boehringer Ingelheim Investigational Site
city: Monza
country: Italy
facility: 1123.28.39011 Boehringer Ingelheim Investigational Site
city: Pescia (Pistoia)
country: Italy
facility: 1123.28.39082 Boehringer Ingelheim Investigational Site
city: Pescia (Pistoia)
country: Italy
facility: 1123.28.39083 Boehringer Ingelheim Investigational Site
city: Pistoia
country: Italy
facility: 1123.28.39008A Boehringer Ingelheim Investigational Site
city: Pistoia
country: Italy
facility: 1123.28.39081 Boehringer Ingelheim Investigational Site
city: Sanremo (IM)
country: Italy
facility: 1123.28.39041 Boehringer Ingelheim Investigational Site
city: Hamar
country: Norway
facility: 1123.28.47005 Boehringer Ingelheim Investigational Site
city: Oslo
country: Norway
facility: 1123.28.47001 Boehringer Ingelheim Investigational Site
city: Oslo
country: Norway
facility: 1123.28.47002 Boehringer Ingelheim Investigational Site
city: Lima
country: Peru
facility: 1123.28.19001 Boehringer Ingelheim Investigational Site
city: Lima
country: Peru
facility: 1123.28.19004 Boehringer Ingelheim Investigational Site
city: Gniezno
country: Poland
facility: 1123.28.48002 Boehringer Ingelheim Investigational Site
city: Gniezno
country: Poland
facility: 1123.28.48006 Boehringer Ingelheim Investigational Site
city: Grodzisk Wielopolski
country: Poland
facility: 1123.28.48009 Boehringer Ingelheim Investigational Site
city: Poznan
country: Poland
facility: 1123.28.48001 Boehringer Ingelheim Investigational Site
city: Chelyabinsk
country: Russian Federation
facility: 1123.28.70005 Boehringer Ingelheim Investigational Site
city: Chelyabinsk
country: Russian Federation
facility: 1123.28.77005 Boehringer Ingelheim Investigational Site
city: Ekaterinburg
country: Russian Federation
facility: 1123.28.70001 Boehringer Ingelheim Investigational Site
city: Ekaterinburg
country: Russian Federation
facility: 1123.28.77001 Boehringer Ingelheim Investigational Site
city: Irkutsk
country: Russian Federation
facility: 1123.28.70009 Boehringer Ingelheim Investigational Site
city: Irkutsk
country: Russian Federation
facility: 1123.28.77009 Boehringer Ingelheim Investigational Site
city: Kemerovo
country: Russian Federation
facility: 1123.28.70002 Boehringer Ingelheim Investigational Site
city: Kemerovo
country: Russian Federation
facility: 1123.28.77002 Boehringer Ingelheim Investigational Site
city: Murmansk
country: Russian Federation
facility: 1123.28.70008 Boehringer Ingelheim Investigational Site
city: Murmansk
country: Russian Federation
facility: 1123.28.77008 Boehringer Ingelheim Investigational Site
city: Nizhny Novgorod
country: Russian Federation
facility: 1123.28.77003 Boehringer Ingelheim Investigational Site
city: Nizhnyi Novgorod
country: Russian Federation
facility: 1123.28.70003 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 1123.28.70006 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 1123.28.70007 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 1123.28.77006 Boehringer Ingelheim Investigational Site
city: Tomsk
country: Russian Federation
facility: 1123.28.70004 Boehringer Ingelheim Investigational Site
city: Tomsk
country: Russian Federation
facility: 1123.28.77004 Boehringer Ingelheim Investigational Site
city: Belgrade
country: Serbia
facility: 1123.28.38101 Boehringer Ingelheim Investigational Site
city: Belgrade
country: Serbia
facility: 1123.28.38103 Boehringer Ingelheim Investigational Site
city: Belgrade
country: Serbia
facility: 1123.28.38104 Boehringer Ingelheim Investigational Site
city: Nis
country: Serbia
facility: 1123.28.38106 Boehringer Ingelheim Investigational Site
city: Nis
country: Serbia
facility: 1123.28.38107 Boehringer Ingelheim Investigational Site
city: Sabac
country: Serbia
facility: 1123.28.38109 Boehringer Ingelheim Investigational Site
city: Smederevo
country: Serbia
facility: 1123.28.38108 Boehringer Ingelheim Investigational Site
city: Vrsac
country: Serbia
facility: 1123.28.38110 Boehringer Ingelheim Investigational Site
city: Zajecar
country: Serbia
facility: 1123.28.38111 Boehringer Ingelheim Investigational Site
city: Zemun
country: Serbia
facility: 1123.28.38104 Boehringer Ingelheim Investigational Site
city: Zemun
country: Serbia
facility: 1123.28.38105 Boehringer Ingelheim Investigational Site
city: Almeria
country: Spain
facility: 1123.28.34001 Boehringer Ingelheim Investigational Site
city: Granada
country: Spain
facility: 1123.28.34004 Boehringer Ingelheim Investigational Site
city: Huelva
country: Spain
facility: 1123.28.34003 Boehringer Ingelheim Investigational Site
city: Madrid
country: Spain
facility: 1123.28.34007 Boehringer Ingelheim Investigational Site
city: Malaga
country: Spain
facility: 1123.28.34002 Boehringer Ingelheim Investigational Site
city: Salamanca
country: Spain
facility: 1123.28.34011 Boehringer Ingelheim Investigational Site
city: Belfast
country: United Kingdom
facility: 1123.28.44600 Boehringer Ingelheim Investigational Site
city: Belfast
country: United Kingdom
facility: 1123.28.44610 Boehringer Ingelheim Investigational Site
city: Bristol
country: United Kingdom
facility: 1123.28.44210 Boehringer Ingelheim Investigational Site
city: Bristol
country: United Kingdom
facility: 1123.28.44220 Boehringer Ingelheim Investigational Site
city: Chippenham
country: United Kingdom
facility: 1123.28.44200 Boehringer Ingelheim Investigational Site
city: Dundonald
country: United Kingdom
facility: 1123.28.44620 Boehringer Ingelheim Investigational Site
city: Leicester
country: United Kingdom
facility: 1123.28.44110 Boehringer Ingelheim Investigational Site
city: Newry
country: United Kingdom
facility: 1123.28.44630 Boehringer Ingelheim Investigational Site
city: Nottingham
country: United Kingdom
facility: 1123.28.44100 Boehringer Ingelheim Investigational Site
Study officials:
affiliation: Boehringer Ingelheim
name: Boehringer Ingelheim
role: STUDY_CHAIR
References:
citation: Shavadia J, Welsh R, Gershlick A, Zheng Y, Huber K, Halvorsen S, Steg PG, Van de Werf F, Armstrong PW. Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Study. J Am Heart Assoc. 2016 Jun 13;5(6):e003559. doi: 10.1161/JAHA.116.003559.
citation: Bainey KR, Fresco C, Zheng Y, Halvorsen S, Carvalho A, Ostojic M, Goldstein P, Gershlick AH, Westerhout CM, Van de Werf F, Armstrong PW; STREAM Investigators. Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction. Heart. 2016 Apr;102(7):527-33. doi: 10.1136/heartjnl-2015-308075. Epub 2016 Jan 18.
citation: Shavadia J, Zheng Y, Dianati Maleki N, Huber K, Halvorsen S, Goldstein P, Gershlick AH, Wilcox R, Van de Werf F, Armstrong PW. Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction? J Am Heart Assoc. 2015 Aug 24;4(8):e002049. doi: 10.1161/JAHA.115.002049.
citation: Gershlick AH, Westerhout CM, Armstrong PW, Huber K, Halvorsen S, Steg PG, Ostojic M, Goldstein P, Carvalho AC, Van de Werf F, Wilcox RG. Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged. Heart. 2015 May;101(9):692-8. doi: 10.1136/heartjnl-2014-306686. Epub 2015 Feb 17.
citation: Sinnaeve PR, Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Lambert Y, Danays T, Soulat L, Halvorsen S, Ortiz FR, Vandenberghe K, Regelin A, Bluhmki E, Bogaerts K, Van de Werf F; STREAM investigators. ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up. Circulation. 2014 Sep 30;130(14):1139-45. doi: 10.1161/CIRCULATIONAHA.114.009570. Epub 2014 Aug 26.
citation: Dianati Maleki N, Van de Werf F, Goldstein P, Adgey JA, Lambert Y, Sulimov V, Rosell-Ortiz F, Gershlick AH, Zheng Y, Westerhout CM, Armstrong PW. Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial. Heart. 2014 Oct;100(19):1543-9. doi: 10.1136/heartjnl-2014-306023. Epub 2014 Jun 10.
citation: Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, Carvalho AC, Nanas J, Arntz HR, Halvorsen S, Huber K, Grajek S, Fresco C, Bluhmki E, Regelin A, Vandenberghe K, Bogaerts K, Van de Werf F; STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013 Apr 11;368(15):1379-87. doi: 10.1056/NEJMoa1301092. Epub 2013 Mar 10.
citation: Armstrong PW, Gershlick A, Goldstein P, Wilcox R, Danays T, Bluhmki E, Van de Werf F; STREAM Steering Committee. The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. Am Heart J. 2010 Jul;160(1):30-35.e1. doi: 10.1016/j.ahj.2010.04.007.